ultra mega song Solana formed a bullish cup and handle pattern, testing a crucial supply zone. Strong technical indicators and social dominance suggested a higher likelihood of a bullish breakout. Solana [SOL] was building a strong bullish setup with a textbook cup and handle pattern forming on the weekly chart, hinting at a potential breakout. At press time, SOL traded at $238.32, up 1.08% in the last 24 hours. The price is now testing a critical supply zone, and a successful breakout here could trigger a significant upward rally. Traders and investors are eager to see if SOL can maintain its momentum and push through this resistance. Is SOL on the verge of a breakout? Solana's weekly chart clearly displays a classic cup and handle formation, a bullish pattern that suggests a potential upward movement. The price is nearing a strong supply zone, a crucial resistance point. A breakout above this zone would likely bring in more buyers, driving SOL higher. However, a rejection would result in a pullback. Therefore, traders... Erastus Chami

Ousted Syrian leader Assad flees to Moscow after fall of Damascus, Russian state media say DAMASCUS, Syria (AP) — Russia media say ousted Syrian leader Bashar Assad has fled to Moscow and received asylum from his longtime ally. The reports came hours after a stunning rebel advance swept into Damascus to cheers and ended the Assad family’s 50 years of iron rule. Thousands of Syrians poured into streets echoing with celebratory gunfire, joyful after a stifling, nearly 14-year civil war. But the swiftly moving events raised questions about the future of the country and the wider region. The rebels face the daunting task of healing bitter divisions in a country still split among armed factions. One rebel commander said “we will not deal with people the way the Assad family did." Analysis: Collapse of Syria's Assad is a blow to Iran's 'Axis of Resistance' MANAMA, Bahrain (AP) — For Iran’s theocratic government, it keeps getting worse. Its decadeslong strategy of building an “Axis of Resistance” supporting militant groups and proxies around the region is falling apart. Hamas has been batttered by Israel's campaign in Gaza. In Lebanon, Israeli bombardment has crippled Iran’s most powerful ally, Hezbollah, even as Israel has launched successful airstrikes openly inside of Iran for the first time. And now Iran’s longtime stalwart ally and client in Syria, President Bashar Assad, is gone. Who is Abu Mohammed al-Golani, the leader of the insurgency that toppled Syria's Assad? BEIRUT (AP) — Abu Mohammed al-Golani, the militant leader who led the stunning insurgency that toppled Syria’s President Bashar Assad, has spent years working to remake his public image and that of his fighters. He renounced longtime ties to al-Qaida and depicts himself as a champion of pluralism and tolerance. The extent of that transformation from jihadi extremist to would-be state builder is now put to the test. The 42-year-old al-Golani is labeled a terrorist by the United States. He has not appeared publicly since Damascus fell early Sunday. But he and his insurgent force, Hayat Tahrir al-Sham, stand to be a major player in whatever comes next. Trump says he can't guarantee tariffs won't raise US prices and won't rule out revenge prosecutions WASHINGTON (AP) — Donald Trump says he can’t guarantee his promised tariffs on key U.S. foreign trade partners won’t raise prices for American consumers. And he's suggesting once more that some political rivals and federal officials who pursued legal cases against him should be imprisoned. The president-elect made the comments in a wide-ranging interview with NBC’s “Meet the Press” that aired Sunday. He also touched on monetary policy, immigration, abortion and health care, and U.S. involvement in Ukraine, Israel and elsewhere. Trump often mixed declarative statements with caveats, at one point cautioning “things do change.” A timeline of the murder of UnitedHealthcare CEO Brian Thompson and the search for his killer NEW YORK (AP) — The search for UnitedHealthcare CEO Brian Thompson’s killer has stretched into a fifth day — and beyond New York City. Police say it appears the man left the city on a bus soon after Wednesday's shooting outside the New York Hilton Midtown. The suspect is seen on video at an uptown bus station about 45 minutes later. The FBI is offering a $50,000 reward for information leading to an arrest and conviction. Police believe that words found written on ammunition at the shooting scene, including “deny," “defend” and "depose,” suggest a motive driven by anger toward the healthcare company. The words mimic a phrase used by insurance industry critics. Trump calls for immediate ceasefire in Ukraine and says a US withdrawal from NATO is possible WASHINGTON (AP) — Donald Trump is pushing Russian leader Vladimir Putin to act to reach an immediate ceasefire with Ukraine. Trump describes it as part of his active efforts as president-elect to end the war despite being weeks from taking office. Trump also said he would be open to reducing military aid to Ukraine and pulling the United States out of NATO. Those are two threats that have alarmed Ukraine, NATO allies and many in the U.S. national security community. Ukrainian President Volodymyr Zelenskyy says any deal would have to pave the way to a lasting peace. The Kremlin's spokesman says Moscow is open to talks with Ukraine. Gaza health officials say latest Israeli airstrikes kill at least 14 including children DEIR AL BALAH, Gaza Strip (AP) — Palestinian health officials say Israeli airstrikes in central Gaza have killed at least 14 people including children, while the bombing of a hospital in northern Gaza has wounded a half-dozen patients. Israel’s military continues its latest offensive against Hamas militants in northern Gaza, whose remaining Palestinians have been almost completely cut off from the rest of the territory amid a growing humanitarian crisis. One airstrike flattened a residential building in the urban Bureij refugee camp Sunday afternoon. That's according to the Al-Aqsa Martyrs Hospital in the nearby city of Deir al-Balah, where the casualties were taken. South Korea's democracy held after a 6-hour power play. What does it say for democracies elsewhere? SEOUL, South Korea (AP) — A short-lived martial law decree by South Korea's leader last week raised worries about budding authoritarianism around the world. In the end, though, democracy prevailed. President Yoon Suk Yeol announced that he was declaring martial law and giving his government sweeping powers to crack down on protesters, ban political parties and control the media. Members of the military blocked lawmakers from using the legislature's constitutional power to cancel the power grab. But the National Assembly within hours unanimously voted to do so. The stars will come out at the Kennedy Center for Coppola, the Grateful Dead, Raitt and Sandoval WASHINGTON (AP) — Celebrities, cultural icons and a few surprise guests are gathering for the annual Kennedy Center Honors celebration in Washington. This year’s recipients of the lifetime achievement award for artistic accomplishment are director Francis Ford Coppola, the Grateful Dead, jazz trumpeter Arturo Sandoval, and singer-songwriter Bonnie Raitt. In addition, the venerable Harlem theater The Apollo, which has launched generations of Black artists, is being recognized Sunday night. There will be personalized tributes with performances and testimonials from fellow artists during the gala at the John F. Kennedy Center for the Performing Arts. College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out SMU captured the last open spot in the 12-team College Football Playoff, bumping Alabama to land in a bracket that placed undefeated Oregon at No. 1. The selection committee preferred the Mustangs, losers of a heartbreaker in the Atlantic Coast Conference title game, who had a far less difficult schedule than Alabama of the SEC but one fewer loss. The inaugural 12-team bracket marks a new era for college football, though the Alabama-SMU debate made clear there is no perfect formula. The tournament starts Dec. 20-21 with four first-round games. It concludes Jan. 20 with the national title game in Atlanta.A week after a demoralizing loss to the Tennessee Titans, the AFC South-leading Houston Texans might have a perfect opportunity to reboot when they face the host Jacksonville Jaguars on Sunday. Then again, maybe not. It depends, Houston coach DeMeco Ryans said, if the Texans (7-5) are "locked in" and able to make a December push. "I just look at it as being intensely focused on your job and being where you're supposed to be, executing the minor details of your job," Ryans said. "It all comes down to minor, minute details that you get exploited if you don't do them the correct way and teams find those and they make you pay. "And a lot of the things, as I talked to our guys about, are things that we can control." Jacksonville (2-9), sitting at the bottom of the AFC South, is coming off a humiliating 52-6 loss to the Detroit Lions. It marked the fourth straight setback for the Jaguars, who had dropped their previous three games by a combined 13 points. Jaguars coach Doug Pederson noted that changes are coming, although he opted not to show his cards. "I'm not going to get into the whole details of things, but there are things in the run game that we have to get back to," Pederson said. "Even in the passing game, tweaking some things there. There are things that can, hopefully, help our production over the last six weeks." One of those things could be the return of starting quarterback Trevor Lawrence, who has not played since Nov. 3 due to a left shoulder injury. Lawrence was a limited participant during practice on Wednesday, with Pederson telling reporters Monday that the signal-caller's status for Sunday would be determined as the week progresses. Pederson has also had his eye on Houston quarterback C.J. Stroud, who has run into some struggles during his sophomore season. Stroud has thrown nine interceptions in 12 games (all starts) after throwing only five as a rookie. He was picked off twice in the 32-27 setback against Tennessee, also throwing for 247 yards and two touchdowns on 20-for-33 passing. Pederson still believes the 23-year-old can hurt the Jaguars, though. "Playing the quarterback position is hard," Pederson said. "I don't know everything that goes on down there. I'm sure there's been injury, guys have missed (time). He's missed his playmakers from time to time. And then there's the film. There's the film out there." The Texans have lost three of their past four games and four of their past six as defenses continue to solve Stroud. Defensive ends Will Anderson Jr. (ankle) and Denico Autry (knee) were among those who didn't practice for Houston on Wednesday, and safety Jalen Pitre is expected to miss several weeks because of a shoulder injury. Linebacker Yasir Abdullah (hamstring) was the only Jaguar to miss practice on Wednesday. Cornerback Tyson Campbell (shoulder) joined Lawrence as limited. Sunday marks the second meeting of the season between the teams. The Texans topped Jacksonville 24-20 back on Sept. 29. This article first appeared on Field Level Media and was syndicated with permission.

Tiger Woods and Rory McIlroy have created 'totally different sport' as TGL details emerge

Showcasing Italian culture, tradition, cuisine and its position in innovation and agri-tech, the Villaggio Italia exhibition is beckoning visitors at Old Doha Port. Open until Sunday (December 22), the exhibition featuring Italian products is a part of the global tour of the historic sailing ship *Amerigo Vespucci, which arrived in Doha to convey the message of peace and partnership and testify to the diplomatic relations between Qatar and Italy. While opening the exhibition Thursday, Italian Agriculture Minister Francesco Lollobrigida said that the Villaggio Italia is dedicated to featuring the entire Italy with its characteristics. “At Expo 2023 Doha, Italy participated while showcasing the innovations in the agriculture sector and technology,” he said, adding that Italy can help Qatar and the countries in the region attain development in the agriculture sector. "Italy and Qatar have a good relationship in various sectors,” he said. “Italian presence is visible in Qatar in the sports, agriculture and technology sectors,” the minister continued. “Italy is known for innovations in the agriculture sector and high-quality agricultural products. And this expertise can be used by the countries in the region.” “The co-operation can lead to establishing a supply chain to achieve food security,” he said. The exhibition is a journey into the Italian taste and artisan tradition. The “Anima Italia” at the exhibition hosts the vegetable garden of Italian excellence with a space of nature dedicated to typical Italian crops. The corner for distinguished Italian cuisine is a tribute to the rich tradition of Mediterranean cuisine and the authentic flavours of Italy. The Villaggio Italia also offers visitors a unique experience to explore cultural activities where Italian music and art performances welcome the visitors. The *Amerigo Vespucci, the historic sailing ship and training ship of the Italian navy, docked at the Old Doha Port for the first time in its 93-year history. Doha is the 30th stop on the Vespucci World Tour which started from Italy on July 1 last year. The *Vespucci is open to the public free of charge from 10am-11pm, until tomorrow. The ship will depart on Sunday. This is the sixth appointment with the Villaggio Italia after those in Los Angeles, Tokyo, Darwin, Singapore and Mumbai. The event in Qatar is with the support of the Italian embassy in Doha, the Italian Trade Agency, and local partners Qatar Tourism, Katara – the Cultural Village and Old Doha Port. Related Story Italian ship Amerigo Vespucci in Doha Ode to Our Land to screen at Msheireb Downtown Doha

RICHMOND, Ky. (AP) — Matt Morrissey threw a 67-yard touchdown pass to Marcus Calwise Jr. that ended the scoring midway through the fourth quarter and Eastern Kentucky beat North Alabama 21-15 on Saturday for its fifth straight win. TJ Smith drove North Alabama to the EKU 45-yard line before he threw an interception to Mike Smith Jr. to end the game. Smith threw a 24-yard touchdown pass to Dakota Warfield to give North Alabama a 15-14 lead with 10:37 to play. Morrissey completed 9 of 15 passes for 154 yards and added 60 yards on the ground with a touchdown run. Brayden Latham added 103 yards rushing on 19 carries that included a 2-yard score for Eastern Kentucky (8-4, 6-2 United Athletic Conference). Smith was 23-of-39 passing for 325 yards with a touchdown and two interceptions for North Alabama (3-9, 2-5). Tanaka Scott had 109 yards receiving and a touchdown catch. ___ Get alerts on the latest AP Top 25 poll throughout the season. ___ AP college football: and The Associated Press

Surprise Paramedic of the Year dies after battling cancerRobinson Helicopter's Symmetrical Horizontal Stabilizer Now Approved for All Models by European Union Aviation Safety Agency (EASA), Argentina, Japan, and India

WASHINGTON (AP) — Working-class voters helped Republicans make steady election gains this year and expanded a coalition that increasingly includes rank-and-file union members, a political shift spotlighting one of President-elect Donald Trump’s latest Cabinet picks: a GOP congresswoman, who has drawn labor support, to be his labor secretary. Oregon Rep. Lori Chavez-DeRemer narrowly lost her bid for a second term this month, despite strong backing from union members, a key part of the Democratic base but gravitating in the Trump era toward a Republican Party traditionally allied with business interests. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.